Doctors Note Logo

Published on: 9/24/2026

Can antidepressants like citalopram help with hot flashes?

Yes, certain antidepressants can ease hot flashes, and several factors determine whether they are right for you, so see below for the complete answer. Low-dose SSRIs and SNRIs such as citalopram, escitalopram, paroxetine, venlafaxine, and desvenlafaxine have been shown to reduce the frequency and severity of hot flashes and night sweats, often within one to two weeks, making them a useful nonhormonal option for people who cannot or prefer not to take estrogen. Doses used for hot flashes are typically lower than those used for depression, and benefits vary by drug, with paroxetine and venlafaxine having the strongest evidence and paroxetine requiring caution in anyone taking tamoxifen. Possible side effects include nausea, dry mouth, dizziness, sleep changes, and sexual side effects, and these medicines should be tapered rather than stopped abruptly, so the details below are important before starting or switching. Because hot flashes can also stem from thyroid disease, medications, infection, anxiety, or other conditions, it is worth confirming what is actually driving your symptoms.

A free, instant, online symptom check takes only a few minutes, asks the same kinds of questions a clinician would, and helps you see which causes best match your pattern of hot flashes and what other symptoms may matter. Knowing that before your appointment makes it far easier to ask about low-dose citalopram or other options and to decide how soon you should be seen.

Last reviewed for medical accuracy: 09/24/2026

answer background

Explanation

Can Antidepressants Like Citalopram Help With Hot Flashes?

Hot flashes are one of the most common and disruptive symptoms of menopause and perimenopause. They can range from mild warmth to intense, drenching sweats that interfere with daily life and sleep. While hormone replacement therapy (HRT) remains the gold standard for relief, not every woman can or wants to use estrogen. In recent years, certain antidepressants—particularly selective serotonin reuptake inhibitors (SSRIs) like citalopram—have emerged as non-hormonal options for reducing hot flashes.

Below, we explain how citalopram works, review the evidence, discuss benefits and risks, and outline when to seek further medical advice.


How Citalopram Works

  • Citalopram is an SSRI commonly prescribed for depression and anxiety.
  • It increases serotonin levels in the brain, which can influence the body’s temperature regulation.
  • By stabilizing neurotransmitters involved in heat control, SSRIs may reduce the frequency and severity of hot flashes.
  • Despite its effects on mood and heat regulation, citalopram is not classified as a controlled substance under U.S. Drug Enforcement Administration (DEA) regulations (citalopram controlled substance status: none).

What the Research Shows

  1. Clinical Trials

    • A 2005 randomized trial in Obstetrics & Gynecology found a 43% reduction in hot flashes with 10–20 mg of citalopram daily, versus 15% in placebo.
    • Results are similar to studies of paroxetine and venlafaxine, where up to 60% of women saw significant relief.
  2. Systematic Reviews

    • The Cochrane Collaboration reviewed non-hormonal treatments and concluded that SSRIs and serotonin-norepinephrine reuptake inhibitors (SNRIs) can reduce hot flashes by about 50% compared to placebo.
  3. Professional Guidelines

    • The North American Menopause Society (NAMS) and NICE (UK) recognize low-dose SSRIs/SNRIs as second-line options for women who cannot use HRT.

Benefits of Using Citalopram for Hot Flashes

  • Non-hormonal: Safe for women with a history of breast cancer or those at risk of thromboembolism.
  • Dual action: May improve mood, sleep quality, and anxiety alongside reducing hot flashes.
  • Convenience: Once-daily dosing; available in tablet form or liquid for dose adjustments.
  • Regulatory status: Not a controlled substance, making it easier to prescribe and refill.

Limitations and Considerations

  • Onset of action: May take 4–6 weeks to achieve full hot-flash relief.
  • Symptom reduction: Average 40–50% improvement—often less dramatic than with HRT.
  • Individual response: Some women do not respond; dose adjustments or alternative SSRIs/SNRIs may be needed.
  • Drug interactions: Metabolism via liver enzymes (CYP2C19 and CYP3A4) means potential interactions with other medications.

Potential Side Effects

While many tolerate citalopram well, common side effects include:

  • Gastrointestinal upset: nausea, diarrhea
  • Headaches or dizziness
  • Sleep disturbances: insomnia or drowsiness
  • Sexual changes: reduced libido or difficulty achieving orgasm
  • Weight changes: modest gain or loss

Rare but serious risks:

  • QT-interval prolongation: higher doses (> 40 mg/day) can affect heart rhythm
  • Serotonin syndrome: when combined with other serotonergic drugs
  • Suicidal thoughts: particularly in young adults under 25

If you experience chest pain, severe dizziness, fainting, or rapid heartbeat, seek medical attention immediately.


Comparing Alternatives

Treatment Typical Reduction in Hot Flashes Key Pros Key Cons
Citalopram (SSRI) 40–50% Non-hormonal, mood lift Takes weeks; side effects common
Paroxetine (SSRI) 50–60% FDA-approved for menopause Sexual side effects
Venlafaxine (SNRI) 50% Quick onset (2 weeks) Blood pressure elevation
Gabapentin 45–55% No sexual side effects Dizziness, sedation
Clonidine 30% Low cost Dry mouth, fatigue

Special Notes on Citalopram Controlled Substance Status

  • The keyword citalopram controlled substance is often searched by those concerned about prescription rules.
  • Citalopram is not a scheduled drug under the Controlled Substances Act.
  • This means fewer restrictions on prescribing and refilling compared to benzodiazepines or opioids.

Lifestyle and Self-Care Strategies

Medications work best when combined with healthy habits:

  • Keep cool: lightweight clothing, fans, air conditioning
  • Avoid triggers: spicy foods, caffeine, alcohol, hot beverages
  • Practice relaxation: deep breathing, yoga, mindfulness
  • Stay hydrated and eat balanced, nutrient-rich meals
  • Maintain a consistent sleep schedule

When to Talk to Your Doctor

You should speak to a doctor if you experience:

  • Hot flashes that severely disrupt daily life or sleep
  • Symptoms of depression or anxiety
  • Cardiovascular risk factors (e.g., QT prolongation, high blood pressure)
  • Persistent or worsening side effects on medication
  • Any chest pain, fainting, severe headaches, or suicidal thoughts

For a quick, preliminary check, try a free, online symptom check, using the doctor approved Ubie Symptom Checker to see if your symptoms align with menopause or another condition.


Final Thoughts

Citalopram and other SSRIs/SNRIs offer a valuable non-hormonal option for many women struggling with hot flashes. While they don’t work as fast or as completely as HRT, they can significantly improve quality of life—especially for those who cannot take hormones.

Always weigh the benefits against potential side effects, and never start or stop any medication without discussing it with your doctor. If your hot flashes are intense, sudden, or accompanied by worrying symptoms, seek immediate medical advice, as they could signal a more serious issue.

Your health is unique—partner with your healthcare provider to find the best, safest approach for you.

(References)

  • * Reid R, Abramson BL, Blake J, Desindes S, Dodin S, Johnston S, Rowe T, Sodhi N, Wilks P, Wolfman W, MENOPAUSE AND OSTEOPOROSIS WORKING GROUP. Managing menopause. J Obstet Gynaecol Can. 2014 Sep;36(9):830-833. doi: 10.1016/S1701-2163(15)30487-4. PMID: 25222364.

  • * Hill DA, Crider M, Hill SR. Hormone Therapy and Other Treatments for Symptoms of Menopause. Am Fam Physician. 2016 Dec 1;94(11):884-889. PMID: 27929271.

  • * Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN, Board of Trustees for The North American Menopause Society (NAMS) and the Women and Mood Disorders Task Force of the National Network of Depression Centers. Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations. Menopause. 2018 Oct;25(10):1069-1085. doi: 10.1097/GME.0000000000001174. PMID: 30179986.

  • * Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. J Womens Health (Larchmt). 2019 Feb;28(2):117-134. doi: 10.1089/jwh.2018.27099.mensocrec. Epub 2018 Sep 5. PMID: 30182804.

  • * Landy K, Rosani A, Estevez R. Escitalopram. 2023 Jan. PMID: 32491666.

  • * Proserpio P, Marra S, Campana C, Agostoni EC, Palagini L, Nobili L, Nappi RE. Insomnia and menopause: a narrative review on mechanisms and treatments. Climacteric. 2020 Dec;23(6):539-549. doi: 10.1080/13697137.2020.1799973. Epub 2020 Sep 3. PMID: 32880197.

  • * Grigolon RB, Ceolin G, Deng Y, Bambokian A, Koning E, Fabe J, Lima M, Gerchman F, Soares CN, Brietzke E, Gomes FA. Effects of nutritional interventions on the severity of depressive and anxiety symptoms of women in the menopausal transition and menopause: a systematic review, meta-analysis, and meta-regression. Menopause. 2023 Jan 1;30(1):95-107. doi: 10.1097/GME.0000000000002098. Epub 2022 Nov 7. PMID: 36576445.

  • * Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. JAMA. 2023 Feb 7;329(5):405-420. doi: 10.1001/jama.2022.24140. PMID: 36749328.

  • * Lin KL, Talmor B, Crumbaker M, Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025 Aug 7;110(9):2509-2519. doi: 10.1210/clinem/dgaf302. PMID: 40397707.

  • * Saadedine M, Banks V, Dinkel-Keuthage C, Janssenswillen C, Lavallee M, Moeller C, Schoof N, Vizcaya D, Francuski M, Golozar A, Römer T, Kubba A. Treatment patterns in women with breast cancer and endocrine therapy-related menopausal symptoms: a cohort study from the United States, United Kingdom, and Germany. Menopause. 2025 Dec 1;32(12):1111-1119. doi: 10.1097/GME.0000000000002611. Epub 2025 Dec 1. PMID: 40891646; PMCID: PMC12688460.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.